Musings from The Power List: Miguel Forte - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Musings from The Power List: Miguel Forte

Scientific progress alone isn't enough, says Miguel Forte, who argues that reimbursement and patient access will shape the next decade of cell and gene therapy

  • By

  • Miguel Forte

  • September 8, 2026

  • 5 min

Share

  • 1

    Miguel Forte serves as President of ISCT, focusing on enhancing the society's global presence and establishing its clinical pillar.

  • 2

    Patient access is currently the greatest challenge in cell and gene therapy, hindered by manufacturing capacity, clinical delivery, and reimbursement issues.

  • 3

    Allogeneic cell therapies, especially those from induced pluripotent stem cells, are making significant progress but lack sufficient attention.

  • 4

    Faster clinical trial approvals and pragmatic health technology assessments are essential for accelerating progress in cell and gene therapy.

  • 5

    The integration of improved gene editing and AI is expected to transform drug development, making it more proactive and design-oriented.

Original Source(s)

Musings from The Power List: Miguel Forte

  • by Miguel Forte

  • September 8, 2026

Related Content

Evidence of nosocomial human-to-human transmission of Dabie bandavirus: a clinical, epidemiological, and virological investigation

This Week’s CGT News: Bristol Myers Ends Cellares Manufacturing Agreement

A first-in-human study reduces stem-cell collection and manufacturing times, Bristol Myers ends its Breyanzi agreement with Cellares, and two approaches strengthen CAR T-cell activity against solid tumors

  • August 31, 2026

  • 5 min
Author Correction: Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms